Fourteen (14) patients aged 3 to 18 years old, with severe (12) or moderate (2) hemophilia A (12) or B (2), and one patient with severe vWD had their treatment optimised during the 1-year period of the projet. The pharmacist made a total of 18 interventions to optimise therapy.

As a result of the pharmacist’s interventions (Table 1 ), the costs of coagulation factors for 15 patients with coagulation disorders extrapolated over 1 year would be reduced by 20.5%, representing savings of $355K CAD/year. After accounting for the $130K CAD investment for the employment of the pharmacist, this represents a total saving of $225K CAD/year, or an average savings of $12.5K CAD per optimization per year.

The largest projected savings were seen in patients initially treated with plasma-derived factors. The seven therapeutic optimizations with Wilate™ as the initial therapy resulted in savings of $409K CAD, or $58K CAD/year per patient. Substitution of Wilate™ with Adynovate™ generated savings of $101K CAD/year per patient, compared with $26K CAD/year per patient for dose optimization of Wilate™ alone. Among the eight hemophilia A patients who underwent product substitution, seven were switched to Adynovate™ for a total projected savings of approximately $281K CAD/year. In total, product substitutions saved $24K CAD/year per patient while keeping the same treatment and optimising doses saved about $15.5K CAD/year per patient.